0

Plasmocure™ – Mycoplasma Elimination Reagent

In very rare cases, mycoplasmas resistant to Plasmocin™ have been reported. To eradicate these mycoplasmas, InvivoGen has developed a new antimycoplasma agent called Plasmocure™.

Plasmocure™ combines two antibiotics that act through different mechanisms of action than those in Plasmocin™. A two-week treatment with Plasmocure™ was found sufficient to completely eliminate the mycoplasmas. A moderate toxicity can be observed during the course of the treatment but full recovery of the cell line is expected once mycoplasmas are eliminated.

Numer kat. Produkt Opakowanie Opis
ant-pc Plasmocure™ 100 mg (1 ml) New antimycoplasma agent
Dodaj do Koszyka Zapytań (możesz wybrać kilka produktów) lub napisz na alab@alab.com.pl

OPIS

Plasmocure™ contains two bactericidal components belonging to different antibiotic families. They both act by inhibiting the protein synthesis but use distinct mechanisms. The first antibiotic binds to the 50S subunit of the ribosome and blocks the peptidyltransferase activity. The second antibiotic binds to the isoleucyl-tRNA synthetase and halts the incorporation of isoleucine into bacterial proteins. These two specific and separate targets are found only in mycoplasmas and Gram positive bacteria, and are completely absent in eukaryotic cells. The cytotoxicity of Plasmocure™ is low, however a slowdown of cell growth may be observed at high concentrations due to the inhibition of mitochondria respiration. At the end of the treatment, when Plasmocure™ is removed from the culture medium, the cells return rapidly to their normal growth rate.

Plasmocure™ is provided as a cell culture tested, sterile filtered solution at a concentration of 100 mg/ml.

Product concentration: 100 mg/ml

Elimination of mycoplasmas in two weeks (recommended concentration of 50 μg/ml)

Shipped at room temperature

 

Plasmocure™ – Mycoplasma Elimination Reagent – Producent Website

DO POBRANIA

× Available from 08:00 to 16:00